Abstract
Surgical cytoreduction has been an integral component of multimodal therapy for metastatic renal cell carcinoma (mRCC) since the seminal reports supporting cytoreductive nephrectomy (CN) were published. 1 Mickisch G.H. Garin A. van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet. 2001; 358: 966-970 Abstract Full Text Full Text PDF PubMed Scopus (1183) Google Scholar , 2 Flanigan R.C. Salmon S.E. Blumenstein B.A. et al. Nephrectomy followed by interferon Alfa-2b compared to interferon Alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 1655-1659 Crossref PubMed Scopus (1415) Google Scholar With the introduction and adoption of targeted therapies and increasing enthusiasm for checkpoint inhibition, the role and sequential timing of CN are now the source of considerable debate. Given the emerging data associating CN with significant perioperative morbidity, critical consideration of optimal patient selection remains paramount.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
